U.S. Legalization Nears: Here Are the Best Cannabis Stocks to Buy

Cannabis stocks like Canopy Growth Corp. (TSX:WEED)(NYSE:CGC) and others are awaiting progress on U.S. legalization.

| More on:
edit Cannabis leaves of a plant on a dark background

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

When this year started, I’d discussed when the United States was set to pursue the legalization of recreational cannabis. Cannabis use has ramped up in North American during the COVID-19 pandemic. Entrepreneurs and investors are scrambling to get in on the largest cannabis market on the planet. Today, I want to look at the best cannabis stocks to snatch up as U.S. legalization talks heat up.

Is cannabis legalization the next big push for the Biden administration?

The giant $1.9 trillion COVID relief bill passed through the House of Representatives late last week. This locked in the first major legislative win for the Biden administration. It also opens the door for the next batch of legislative goals. Cannabis industry enthusiasts are hoping that federal legalization, or at least decriminalization, is on the horizon. This will continue to be positive for cannabis stocks.

A House committee approved a bill in early March that would decriminalize possession of all currently illicit drugs and promote investment into substance abuse mistreatment. This is a solid step forward for the cannabis sector, and for drug treatment across the U.S. in general. Unfortunately, any signs of a push for federal legalization are to be read into at this stage. Top cannabis CEOs remain hopeful that the next two years will bring more concrete news on that front.

These cannabis stocks are poised to benefit from U.S. legalization

Aphria (TSX:APHA)(NASDAQ:APHA) is one of the largest cannabis producers in Canada. Its shares have soared 177% in 2021 as of early afternoon trading on March 16. The stock is up over 750% from the prior year. I’d suggested that investors should target this cannabis stock back in February.

Investors can expect to see its third-quarter fiscal 2021 results in April. In Q2 FY2021, Aphria announced revenue growth of 33% to $160 million. It also reported its seventh straight quarter of increasing positive adjusted EBITDA, rising to $12.6 million in this most recent quarter. Aphria’s cash cost per gram dropped for the fifth straight quarter to $0.79. The company’s CEO stated that Aphria has its eyes on U.S. expansion in early 2021.

Canopy Growth (TSX:WEED)(NYSE:CGC) remains the largest cannabis stock by market cap on the TSX. Shares of Canopy have climbed 26% in 2021 so far. The stock is up over 190% from the prior year.

This top cannabis stock is well positioned to gain from U.S. legalization. Canopy Growth put itself in pole position with its acquisition of Acreage Holdings back in 2019. In Q3 fiscal 2021, Canopy Growth reported net revenue of $152 million — up 23% from the previous year. It posted an adjusted EBITDA loss of $68.4 million, but this was still improved by 29% from the same period last year. No Canadian cannabis stock is better positioned to penetrate the U.S. market in early 2021.

One more cannabis stock to snatch up today

OrganiGram Holdings is another cannabis stock worth watching ahead of potential U.S. legalization. Its shares have shot up 175% in 2021 so far. British American Tobacco recently announced that it took nearly a 20% stake in the Canadian cannabis grower. Organi has also partnered with BAT to research and produce CBD-infused products. This company is geared up for entrance into the lucrative U.S. market.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ambrose O'Callaghan has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends OrganiGram Holdings. The Motley Fool recommends OrganiGram Holdings.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »